CA
NZ
UK
AU
IND
US
Cash on hand climbed to $9.9 million from roughly $3.0 million a few months earlier, whileResearch and Developmentspending contracted to $589,000. The figures highlight a sharper loss profile but a strongerLiquiditycushion as the company advances its lead candidate, Ampligen, into later‑stage trials. Investors must …
Airsculpt Technologies, Inc. (NASDAQ: AIRS) reported a net loss of $1.1 million for the second quarter of 2026, with its earnings per share falling to $-0.02, missing the consensus estimate of $0.01. This performance reflects a continuation of a challenging financial environment as the …
This improvement enhances the company’s ability to fund its growing research pipeline, including the zumilokibart program aimed at atopic dermatitis. The quarter also saw a net loss of $85.9 million, an increase from the $66.1 million loss recorded in the comparable period last year, …
Investors now face a shift in board composition while the firm maintains a marketCapitalizationof $2.1 billion and a year‑to‑date stock rally of 17.5%.
The revenue growth underscores the increasing demand for Axsome's product portfolio, particularly among patients with central nervous system disorders.
The company's shares will continue to trade under the ticker symbol "BSEM". This uplisting is expected to enhance market visibility and liquidity for shareholders, with the company's market capitalization standing at approximately $73 million.
The departure marks the end of a tenure that saw the firm pivot fromPandemic‑era personal protective equipment production to a pure‑play home‑based care model.
Aspire Biopharma Holdings, Inc. has completed the issuance of convertible promissory notes totaling $3.75 million, with an aggregate purchase price of $3 million reflecting a 20% original issue discount. This funding enables the biopharmaceutical company to enhance itsWorking Capitaland pursue additional growth opportunities, indicating …
The dual development of an EPS beat and a massive cost restructuring gives the biotech a clearer path to fund its efzofitimod program through late 2028. Investors see the combination of a modest earnings surprise and a decisive expense‑cut as a sign that the …
Aquestive Therapeutics (Nasdaq:AQST) shares were trading at $4.41 in pre-market activity on August 10, 2026, up 11.93% from the prior close of $3.94. The move followed the company's announcement of positive topline results from human factors and pharmacokinetic studies for its Anaphylm sublingual film, …
Please wait processing your request...